{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:35:00Z","timestamp":1787312100465,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00064203"],"award-info":[{"award-number":["00064203"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To investigate the relationship between\n                      <jats:italic>Clostridium (Clostridioides) difficile<\/jats:italic>\n                      strain characteristics and\n                      <jats:italic>C. difficile<\/jats:italic>\n                      infection (CDI) outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between October and December 2017, 16 hospitals collected epidemiological data according to the European Centre for Disease Prevention and Control (ECDC) surveillance protocol for CDI.\n                      <jats:italic>C. difficile<\/jats:italic>\n                      isolates were characterized by ribotyping, toxin genes detection and antibiotic susceptibility testing to metronidazole, vancomycin and moxifloxacin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall mean CDI incidence density was 4.5 [95% CI 3.6\u20135.3] cases per 10,000 patient-days. From the 433 CDI cases, 330 (76.2%) were healthcare-associated, 52 (12.0%) cases were community-associated or of unknown origin and 51 (11.8%) CDI cases recurrent; a complicated course of CDI was reported in 65 cases (15.0%). Eighty-eight (20.3%) of patients died and 59 of them within 30\u2009days after the CDI diagnosis.<\/jats:p>\n                    <jats:p>\n                      From the 379\n                      <jats:italic>C. difficile<\/jats:italic>\n                      isolates, the most prevalent PCR ribotypes were 001 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009127, 33.5%) and 176 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944, 11.6%). A total of 186 (49.1%) isolates showed a reduced susceptibility to moxifloxacin (&gt;\u20094\u2009mg\/L) and 96.4% of them had Thr82Ile in the GyrA. Nineteen isolates revealed reduced susceptibility to metronidazole and two isolates to vancomycin (&gt;\u20092\u2009mg\/L).\n                    <\/jats:p>\n                    <jats:p>\n                      A fatal outcome was associated with a reduced susceptibility to moxifloxacin, the advanced age of the patients and a complicated course of CDI (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.05). No association between ribotype, binary toxin and a reduced susceptibility to moxifloxacin and complicated course or recurrent CDI was found.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      A reduced susceptibility to moxifloxacin, in causative\n                      <jats:italic>C. difficile<\/jats:italic>\n                      strains was associated with fatal outcome of the patients, therefore it is an important marker in surveillance of CDI.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-020-00765-y","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T03:02:49Z","timestamp":1593486169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients"],"prefix":"10.1186","volume":"9","author":[{"given":"Marcela","family":"Krutova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Capek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elka","family":"Nycova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Vojackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Balejova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Geigerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Tejkalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Havlinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Vagnerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Cermak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ryskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Jezek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Zamazalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Vesela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Kucharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Nemcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Curdova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Nyc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"765_CR1","doi-asserted-by":"publisher","unstructured":"Oren A, Rupnik M. Clostridium difficile and Clostridioides difficile: two validly published and correct names. Anaerobe. 2018;52:125\u20136. https:\/\/doi.org\/10.1016\/j.anaerobe.2018.07.005.","DOI":"10.1016\/j.anaerobe.2018.07.005"},{"key":"765_CR2","volume-title":"Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals","author":"European Centre for Disease Prevention and Control","year":"2013","unstructured":"European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC; 2013."},{"key":"765_CR3","doi-asserted-by":"publisher","unstructured":"Krutova M, Kinross P, Barbut F, Hajdu A, Wilcox MH, Kuijper EJ, Survey contributors. How to: surveillance of Clostridium difficile infections. Clin Microbiol Infect. 2018;24(5):469\u201375. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.008.","DOI":"10.1016\/j.cmi.2017.12.008"},{"key":"765_CR4","doi-asserted-by":"publisher","unstructured":"Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1\u201326. https:\/\/doi.org\/10.1111\/1469-0691.12418.","DOI":"10.1111\/1469-0691.12418"},{"key":"765_CR5","doi-asserted-by":"crossref","unstructured":"Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(16)30514-X.","DOI":"10.1016\/S1473-3099(16)30514-X"},{"key":"765_CR6","doi-asserted-by":"crossref","unstructured":"van Dorp SM, Kinross P, Gastmeier P, Behnke M, Kola A, Delm\u00e9e M, et al. Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013. Euro Surveill. 2016;21(29). https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.29.30293.","DOI":"10.2807\/1560-7917.ES.2016.21.29.30293"},{"key":"765_CR7","unstructured":"European Centre for Disease Prevention and Control. Clostridium difficile infections. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2018."},{"key":"765_CR8","volume-title":"European Surveillance of Clostridium difficile infections. Surveillance protocol version 2.3","author":"European Centre for Disease Prevention and Control","year":"2017","unstructured":"European Centre for Disease Prevention and Control. European Surveillance of Clostridium difficile infections. Surveillance protocol version 2.3. Stockholm: ECDC; 2017."},{"key":"765_CR9","unstructured":"Institute of health information and statistics of the Czech Republic (UZIS). Inpatient care. Prague: UZIS. Czech. Available from: https:\/\/www.uzis.cz\/publikace\/luzkovy-fond-2017. [Accessed 19 Sept 2019]."},{"key":"765_CR10","doi-asserted-by":"publisher","unstructured":"Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63\u201381. https:\/\/doi.org\/10.1016\/j.cmi.2016.03.010.","DOI":"10.1016\/j.cmi.2016.03.010"},{"key":"765_CR11","doi-asserted-by":"crossref","unstructured":"Fawley WN, Knetsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, et al. Development and validation of an internationally-standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PLoS One. 2015;10(2):e0118150. https:\/\/doi.org\/10.1371\/journal.pone.0118150.","DOI":"10.1371\/journal.pone.0118150"},{"issue":"11","key":"765_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1469-0691.2008.02092.x","volume":"14","author":"S Persson","year":"2008","unstructured":"Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA\/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008;14(11):1057\u201364. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02092.x Erratum in: Clin Microbiol Infect. 2009;15(3):296.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"765_CR13","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1128\/AAC.46.11.3418-3421.2002","volume":"46","author":"L Dridi","year":"2002","unstructured":"Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002;46(11):3418\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"765_CR14","unstructured":"Core Team R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. https:\/\/www.R-project.org."},{"key":"765_CR15","doi-asserted-by":"publisher","unstructured":"Krutova M, Matejkova J, Kuijper EJ, Drevinek P, Nyc O. Czech Clostridium difficile study group. Clostridium difficile PCR ribotypes 001 and 176 \u2013 the common denominator of C. difficile infection epidemiology in the Czech Republic, 2014. Euro Surveill. 2016;21(29). https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.29.30296.","DOI":"10.2807\/1560-7917.ES.2016.21.29.30296"},{"key":"765_CR16","doi-asserted-by":"publisher","unstructured":"Krutova M, Matejkova J, Drevinek P, Kuijper EJ, Nyc O, study group. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. Eur J Clin Microbiol Infect Dis. 2017;36(11):2251\u20138. https:\/\/doi.org\/10.1007\/s10096-017-3055-z.","DOI":"10.1007\/s10096-017-3055-z"},{"key":"765_CR17","doi-asserted-by":"publisher","unstructured":"Ooijevaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, Mulder CJJ, Kuijper EJ. Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect. 2018;24(5):452\u201362. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.022.","DOI":"10.1016\/j.cmi.2017.12.022"},{"key":"765_CR18","doi-asserted-by":"publisher","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987\u201394. https:\/\/doi.org\/10.1093\/cid\/ciy149.","DOI":"10.1093\/cid\/ciy149"},{"key":"765_CR19","doi-asserted-by":"publisher","unstructured":"Freeman J, Vernon J, Pilling S, Morris K, Nicholson S, Shearman S, et al. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014. Clin Microbiol Infect. 2018;24(7):724\u201331. https:\/\/doi.org\/10.1016\/j.cmi.2017.10.008.","DOI":"10.1016\/j.cmi.2017.10.008"},{"key":"765_CR20","doi-asserted-by":"publisher","unstructured":"Vernon JJ, Wilcox MH, Freeman J. Effect of fluoroquinolone resistance mutation Thr-82\u2192Ile on Clostridioides difficile fitness. J Antimicrob Chemother. 2019;74(4):877\u201384. https:\/\/doi.org\/10.1093\/jac\/dky535.","DOI":"10.1093\/jac\/dky535"},{"key":"765_CR21","doi-asserted-by":"publisher","unstructured":"He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109\u201313. https:\/\/doi.org\/10.1038\/ng.2478.","DOI":"10.1038\/ng.2478"},{"key":"765_CR22","doi-asserted-by":"publisher","unstructured":"Eyre DW, Davies KA, Davis G, Fawley WN, Dingle KE, De Maio N, Karas A, Crook DW, Peto TEA, Walker AS, Wilcox MH, EUCLID Study Group. Two distinct patterns of Clostridium difficile diversity across Europe indicating contrasting routes of spread. Clin Infect Dis. 2018;67(7):1035\u201344. https:\/\/doi.org\/10.1093\/cid\/ciy252.","DOI":"10.1093\/cid\/ciy252"},{"key":"765_CR23","doi-asserted-by":"publisher","unstructured":"Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, Santhosh K, Mogle JA, Galecki AT, LeBar W, Higgins PD, Young VB, Aronoff DM. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61(2):233\u201341. https:\/\/doi.org\/10.1093\/cid\/civ254.","DOI":"10.1093\/cid\/civ254"},{"key":"765_CR24","doi-asserted-by":"publisher","unstructured":"Inns T, Gorton R, Berrington A, Sails A, Lamagni T, Collins J, Perry J, Hill K, Magee J, Gould K. Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect. 2013;84(3):235\u201341. https:\/\/doi.org\/10.1016\/j.jhin.2013.04.008.","DOI":"10.1016\/j.jhin.2013.04.008"},{"key":"765_CR25","doi-asserted-by":"publisher","unstructured":"Berry CE, Davies KA, Owens DW, Wilcox MH. Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)? Eur J Clin Microbiol Infect Dis. 2017;36(12):2405\u201315. https:\/\/doi.org\/10.1007\/s10096-017-3075-8.","DOI":"10.1007\/s10096-017-3075-8"},{"key":"765_CR26","doi-asserted-by":"publisher","unstructured":"Krutova M, Matejkova J, Nyc O. C. difficile ribotype 027 or 176? Folia Microbiol. 2014;59(6):523\u20136. https:\/\/doi.org\/10.1007\/s12223-014-0323-5.","DOI":"10.1007\/s12223-014-0323-5"},{"key":"765_CR27","doi-asserted-by":"publisher","unstructured":"Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B, Oakley S, O'Connor L, Finney J, Vaughan A, Crook DW, Wilcox MH, Peto TE. Infections in Oxfordshire research database. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis. 2013;56(11):1589\u2013600. https:\/\/doi.org\/10.1093\/cid\/cit127.","DOI":"10.1093\/cid\/cit127"},{"issue":"2","key":"765_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1017\/S095026881500148X","volume":"144","author":"E Reigadas","year":"2016","unstructured":"Reigadas E, Alcal\u00e1 L, Mar\u00edn M, Mart\u00edn A, Iglesias C, Bouza E. Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting. Epidemiol Infect. 2016;144(2):268\u201373. https:\/\/doi.org\/10.1017\/S095026881500148X Erratum in: Epidemiol Infect. 2016;144(12):2691.","journal-title":"Epidemiol Infect"},{"key":"765_CR29","doi-asserted-by":"publisher","unstructured":"Camins BC, Marschall J, DeVader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia. J Hosp Med. 2011;6(6):344\u20139. https:\/\/doi.org\/10.1002\/jhm.877.","DOI":"10.1002\/jhm.877"},{"key":"765_CR30","doi-asserted-by":"publisher","unstructured":"Goldstein E, MacFadden DR, Karaca Z, Steiner CA, Viboud C, Lipsitch M. Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. Int J Antimicrob Agents. 2019;54(1):23\u201334. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.03.004.","DOI":"10.1016\/j.ijantimicag.2019.03.004"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-020-00765-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00765-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T19:47:45Z","timestamp":1624996065000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00765-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00765-y","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For this type of study formal consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}